HRS-4642
Sponsors
Jiangsu HengRui Medicine Co., Ltd., Fudan University, Zhejiang University, West China Hospital, Shanghai Zhongshan Hospital
Conditions
Advanced KRAS G12D Mutant Solid TumorsAdvanced Solid TumorsLocally Advanced Colorectal CancerMetastatic Pancreatic CarcinomaPancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)
Phase 1
Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Active, not recruitingNCT05533463
Start: 2022-09-21End: 2025-12-30Updated: 2025-09-08
A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Active, not recruitingNCT06385678
Start: 2024-07-05End: 2026-08-31Updated: 2025-09-19
Exploratory Clinical Study of HRS-4642 Combined With Adebelimab in the Treatment of Advanced Pancreatic Cancer
RecruitingNCT06427239
Start: 2024-05-29End: 2026-09-30Target: 35Updated: 2024-08-09
A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors
RecruitingNCT06520488
Start: 2024-08-09End: 2027-07-31Target: 118Updated: 2025-09-22
HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma
RecruitingNCT06773130
Start: 2025-02-10End: 2027-03-31Target: 20Updated: 2025-11-17
Phase 2
HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients
RecruitingNCT06770452
Start: 2025-03-25End: 2028-02-01Target: 32Updated: 2025-09-23
An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer
Not yet recruitingNCT06938282
Start: 2025-05-01End: 2029-04-30Target: 60Updated: 2025-04-25
Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
Not yet recruitingNCT07503639
Start: 2026-04-01End: 2030-04-01Target: 134Updated: 2026-03-31